Citation Impact
Citing Papers
LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
2014
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
2015 StandoutNobel
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
2014
Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance
2012
A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody responses in COVID-19 patients
2023 StandoutNobel
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
2014
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen
2013
The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
2011
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization
2012
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
2013
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
2013
Combination cancer immunotherapy and new immunomodulatory targets
2015
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
T cell exhaustion
2011 Standout
Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient
2008
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
2011 StandoutNature
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patients
2007
Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions
2008 StandoutNature
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
2015
ErbBs in lung cancer
2008
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Inversion, duplication, and changes in gene context are associated with human chromosome 18 evolution
2003
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Overcoming T cell exhaustion in infection and cancer
2015
Initial sequence of the chimpanzee genome and comparison with the human genome
2005 StandoutNature
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
2015
Localization of 4q35.2 to the nuclear periphery: is FSHD a nuclear envelope disease?
2004
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
2006
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
Transforming Growth Factor β-Mediated Suppression of Antitumor T Cells Requires FoxP1 Transcription Factor Expression
2014
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
LAG-3 in Cancer Immunotherapy
2010
Therapeutic vaccines for cancer: an overview of clinical trials
2014
Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade
2010
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
2019 Standout
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
Molecular and cellular insights into T cell exhaustion
2015 Standout
Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging
2019
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
2014
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
2009
Genomic Sequence and Transcriptional Profile of the Boundary Between Pericentromeric Satellites and Genes on Human Chromosome Arm 10p
2003
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
2004
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
2006 StandoutScience
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
2015
Coinhibitory Pathways in Immunotherapy for Cancer
2016
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
2005 Standout
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
2012
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells
2014
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Inhibition of Indoleamine 2,3-Dioxygenase Activity by Levo-1-Methyl Tryptophan Blocks Gamma Interferon-Induced Chlamydia trachomatis Persistence in Human Epithelial Cells
2011
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
2008 StandoutNobel
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Structural Dynamics of Eukaryotic Chromosome Evolution
2003 StandoutScience
Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition
2005
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
2005
De novo design of protein logic gates
2020 StandoutScienceNobel
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Works of Amy Beck being referenced
Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
2009
HER-2/ neu Protein Expression and Gene Alteration in Stage I-IIIA Non???Small-Cell Lung Cancer: A Study of 140 Cases Using a Combination of High Throughput Tissue Microarray, Immunohistochemistry, and Fluorescent In Situ Hybridization
2003
Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer
2005
Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism
2014
Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry
2004
Genomic Analysis of Human Chromosome 10q and 4q Telomeres Suggests a Common Origin
2002
A Cascade of Complex Subtelomeric Duplications during the Evolution of the Hominoid and Old World Monkey Genomes
2002
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
2012
Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
2010
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
2003
MCM2 Is an Independent Predictor of Survival in Patients With Non–Small-Cell Lung Cancer
2001